Regenerative Therapy (Jun 2020)

A technique for removing tumourigenic pluripotent stem cells using rBC2LCN lectin

  • Yoshikazu Haramoto,
  • Yasuko Onuma,
  • Shuuji Mawaribuchi,
  • Yoshiro Nakajima,
  • Yasuhiko Aiki,
  • Kumiko Higuchi,
  • Madoka Shimizu,
  • Hiroaki Tateno,
  • Jun Hirabayashi,
  • Yuzuru Ito

Journal volume & issue
Vol. 14
pp. 306 – 314

Abstract

Read online

Introduction: Tumourigenesis attributed to residual undifferentiated cells in a graft is considered to be a significant issue in cell therapy using human pluripotent stem cells. To ensure the safety of regenerative medicine derived from pluripotent stem cells, residual undifferentiated cells must be eliminated in the manufacturing process. We previously described the lectin probe rBC2LCN, which binds harmlessly and specifically to the cell surface of human pluripotent stem cells. We report here a technique using rBC2LCN to remove pluripotent cells from a heterogenous population to reduce the chance of teratoma formation. Methods: We demonstrate a method for separating residual tumourigenic cells using rBC2LCN-bound magnetic beads. This technology is a novel use of their previous discovery that rBC2LCN is a lectin that selectively binds to pluripotent cells. We optimize and validate a method to remove hPSCs from a mixture with human fibroblasts using rBC2LCN-conjugated magnetic beads. Results: Cells with the potential to form teratoma could be effectively eliminated from a heterogeneous cell population with biotin-labelled rBC2LCN and streptavidin-bound magnetic beads. The efficiency was measured by FACS, ddPCR, and animal transplantation, suggesting that magnetic cell separation using rBC2LCN is quite efficient for eliminating hPSCs from mixed cell populations. Conclusions: The removal of residual tumourigenic cells based on rBC2LCN could be a practical option for laboratory use and industrialisation of regenerative medicine using human pluripotent stem cells.

Keywords